In non-small cell lung cancer, low nuclear expression of EP4 predicts improved survival [53]; in breast cancer [22], cytoplasmic expression of EP4 more closely correlates with decreased survival in a pre-clinical model. Here, PTGER4 is linked to breast cancer.